Aslan Pharmaceuticals Pte. Ltd., of Singapore, appointed Andrew Howden an independent non-executive director. Howden is a senior pharmaceutical executive with almost 35 years of experience and has a strong track record in clinical research, business development and commercialisation. Most recently, he was CEO of Inova Pharmaceuticals Pty Ltd., of Thornleigh, Australia, which was acquired by Valeant Pharmaceuticals International Inc., of Laval, Quebec. Read More

Sirtex Medical Ltd., of Sydney, highlighted the publication of results from the SIRFLOX study, a test of SIR-Spheres Y-90 resin microspheres, published online in the Journal of Clinical Oncology. In the primary endpoint of the study, patients with nonresectable liver-dominant or liver-only colorectal cancer who received FOLFOX-based first-line chemotherapy alone had a median progression-free survival (PFS) at any site of 10.2 months vs. 10.7 months in those that received chemotherapy plus SIR-Spheres. Read More

TOKYO – Japan's Anges MG Inc. said a new inflammation treatment it has been developing since 1999 should reach the Japanese market as early as 2018. Read More

HONG KONG – A green light to launch clinical trials in Canada for one of its leading biosimilar products will give South Korean company Alteogen Inc. and its Brazilian partner a boost on the global market. Read More

NEW DELHI – Start-ups and spin-offs could boost India's biopharma sector, as long as the sector as a whole can overcome a series of hurdles, including a chronic shortage of financing. Read More

HONG KONG — Researchers in China have demonstrated that endogenous brown adipose tissue (BAT) is closely related to the development of a polycystic ovarian syndrome (PCOS) phenotype in rats, suggesting that BAT activation might represent a promising therapeutic option for management of PCOS in humans. Read More

TAIPEI, Taiwan – Taiwan's media and capital markets overlooked the positives from OBI Pharma Inc.'s recently reported top-line results from its global phase II/III trial of the OBI-822/821 active immunotherapy for metastatic breast cancer, which missed its primary endpoints, according to Michael Chang, chairman of the Taipei-headquartered company. Read More

HONG KONG – After an 11-month suspension in trading, shares of Hong Kong-listed Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460) plunged more than 54 percent on Monday. Read More